Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Iclusig® (ponatinib) – Expanded indication
March 19, 2024 - Takeda announced the FDA approval of Iclusig (ponatinib), in combination with chemotherapy, for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
